Compare Charles River Laboratories Intl. Inc (CRL) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Orion Office REIT Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.92 (market cap $11.14B), while Orion Office REIT Inc trades at $2.7 (market cap $151.17M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 73.7× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ONL | |
|---|---|---|
Market Cap | $11.14B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $233.60 | $3.04 |
52-Week Low | $145.57 | $1.93 |
Enterprise Value | $14.00B | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
ONL trades at $2.72, down 1.09% today, with a bearish technical signal and negative earnings momentum. The company reported Q1 2026 EPS of -$0.24, missing expectations, while revenue declined to $147.65M in 2025. Despite a low P/B of 0.25, profitability remains weak with a -98.36% net margin. Recent news highlights strategic reviews and portfolio repositioning toward dedicated-use assets.
The outlook is cautious due to persistent losses and declining revenue, though strategic asset sales and debt management provide some stability. Risks include high leverage and office market challenges. Analyst sentiment is mixed with 50% buy ratings. Investment opportunity hinges on successful execution of strategic initiatives amid a difficult operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
